Astley-Sparke Philip
- SEC CIK
- 0001376491
In the past year, 1 open-market sale filing worth $89.7K and no purchases.
Current role at each company
- REPL Replimune Group, Inc.Directoras of Aug 24, 2026
- ENGN enGene Therapeutics Inc.Directoras of Jun 17, 2026
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- $89.7K
- 1 filing
- Net
- −$89.7K
- Bought minus sold
- Companies
- 1
- With open-market trades
Trades
Every Form 4 that lists Astley-Sparke Philip as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
REPL Replimune Group, Inc.
Director5 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| May 20, 2026 (view filing) | May 18 | 2 days | Astley-Sparke PhilipDirector | SSale | −17.7K | $5.08 | −$89.7K | −1.2%1.41M after | |
| May 22, 2025 (view filing) | May 20 | 2 days | Astley-Sparke PhilipDirector | SSale | −32.3K | $8.06 | −$260.2K | −2.2%1.41M after | |
| May 20, 2024 (view filing) | May 16 | 4 days | Astley-Sparke PhilipExecutive Chairman | SSale | −37.9K | $6.47 | −$245.4K | −2.5%1.49M after | |
| May 18, 2023 (view filing) | May 16 | 2 days | Astley-Sparke PhilipChief Executive Officer | SSale | −17.9K | $18.05 | −$323.1K | −1.2%1.53M after | |
| May 18, 2022 (view filing) | May 16 | 2 days | Astley-Sparke PhilipChief Executive Officer | SSale | −9.63K | $14.59 | −$140.5K | −0.7%1.40M after |